TNF Pharmaceuticals Inc

Aktienanalyse zu TNF Pharmaceuticals Inc (TNFA)

$5.200

+2.504 (+48.15%)Zum Schluss

Loading chart…
High
8.940
Open
5.760
VWAP
6.11
Vol
60.74M
Mkt Cap
Low
4.200
Amount
371.34M
EV/EBITDA, TTM
0.00

Q/C Technologies, Inc., formerly TNF Pharmaceuticals, Inc., is focused on blockchain infrastructure. The Company, through a licensing agreement with LightSolver, holds rights to the use of quantum-inspired laser-based processing units (LPUs) that solve compute-intensive combinatorial and physical problems at the speed of light. The Company bridges a disruptive computing paradigm for high-speed photonic computing with cryptocurrency infrastructure development at scale, enabling performance and sustainability for blockchain applications. Lightsolver’s architecture is designed to improve security for blockchain operations for the cryptocurrency industry.

tnfpharma.com

Bewertungskennzahlen

The current forward P/E ratio for TNF Pharmaceuticals Inc (TNFA) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Überbewertet
0.00
Unterbewertet
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Überbewertet
0.00
Unterbewertet
0.00

Alphio AI Price Scenarios for TNFA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TNFA

$0.10

Szenariopreis

B

Base

Base · 50%TNFA

$0.08

Szenariopreis

B

Bear

Bear · 25%TNFA

$0.06

Szenariopreis

Event-Zeitleiste

2025-09-24 (ET)

09:24:44

TNF Pharmaceuticals rebrands as Q/C Technologies

2025-09-17 (ET)

09:33:44

TNF Pharmaceuticals Restores Compliance with Nasdaq Regulations

2025-09-02 (ET)

09:26:32

PharmaCyte Biotech Boosts Investment in TNF Pharmaceuticals by $3 Million

09:24:59

TNF Pharmaceuticals Reveals $7 Million Private Placement Deal

09:24:11

TNF Pharmaceuticals acquires rights to LightSolver technology for cryptocurrency uses

News

TNFA FAQ — answered by Alphio AI

Q/C Technologies, Inc., formerly TNF Pharmaceuticals, Inc., is focused on blockchain infrastructure. The Company, through a licensing agreement with LightSolver, holds rights to the use of quantum-inspired laser-based processing units (LPUs) that solve compute-intensive combinatorial and physical problems at the speed of light. The Company bridges a disruptive computing paradigm for high-speed photonic computing with cryptocurrency infrastructure development at scale, enabling performance and sustainability for blockchain applications. Lightsolver’s architecture is designed to improve security for blockchain operations for the cryptocurrency industry. It operates in the Healthcare sector.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten